Head-to-head evidence
Paliperidone palmitate (Erzofri) vs Risperidone (Risvan)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Paliperidone palmitate (Erzofri)
Marketed by Luye Pharma Group
NCT03751488 · Phase 1 · completed
In this trial, paliperidone palmitate (INVEGA SUSTENNA) served as the reference comparator against which an investigational competitor formulation, LY03010, was measured for pharmacokinetics; the study was open-label with no blinding, and no results have been posted.
Risperidone (Risvan)
Marketed by Laboratorios Farmacéuticos Rovi, S.A.
NCT03160521 · Phase 3 · completed
The study randomized 438 participants to two risperidone doses or placebo under triple masking, with 390 participants included in the reported primary efficacy analysis. The clinical primary endpoint was the change in PANSS total score, reported as -24.6 and -24.7 points with risperidone versus -11.0 with placebo, but statistical significance for this primary comparison is not stated, so the result remains unclear.
Next expected readout: December 2027 · NCT07047651 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Paliperidone palmitate (Erzofri)'s landscape · Risperidone (Risvan)'s landscape